The Regulatory Arbitrage Strategy What Most People Get Wrong

How did a nineteen-year-old dropout convince world leaders her company was worth $9 billion? Regulatory arbitrage allowed Theranos to exploit a specific legal gray area between medical device laws and laboratory oversight. This strategy involves navigating complex legal frameworks to gain a competitive advantage or bypass traditional barriers to entry.

Elizabeth Holmes knew that obtaining FDA clearance for a new medical device could take years. Instead, she claimed her technology consisted of lab developed tests that only required a simple CLIA certificate. This shift in definitions meant Theranos could launch in retail stores without the rigorous clinical data normally required by federal law.

Winning With Regulatory Arbitrage in Medicine

Regulatory arbitrage occurs when a company exploits the difference between how two different agencies or jurisdictions view the same product. In John Carreyrou’s "Bad Blood," he details how Theranos avoided the Food and Drug Administration (FDA) by framing its Edison device as a tool for a specific laboratory. This allowed the company to scale rapidly while keeping the inner workings of its technology a secret.

The concept matters because it defines the boundary between innovation and non-compliance. Companies often use it to enter markets where traditional regulations are too slow or expensive for a startup to survive. However, as the Theranos story shows, using legal loopholes to hide a non-functional product leads to catastrophic failure.

Theranos was eventually valued at $9 billion by investors like Partner Fund Management, who believed the company had successfully navigated these legal hurdles. The business used its board of directors, filled with former cabinet members, to project an image of absolute business compliance. This authority discouraged regulators from looking too closely at the underlying gaps in the strategy.

Finding Gaps in Regulatory Arbitrage Jurisdiction

Successful arbitrage requires finding a space where two regulators overlap but neither has full control. In the United States, the FDA regulates medical devices, while the Centers for Medicare and Medicaid Services (CMS) regulates laboratory operations. Theranos found its opportunity in the 1976 Medical Device Amendments, which left a gap for tests developed for use within a single lab.

Exploiting Lab Developed Tests for Market Entry

Theranos claimed its devices were merely remote sample-processing units. They argued the machines were "dumb fax machines" that sent data to a central lab in Palo Alto. By doing this, they classified their process under the category of lab developed tests, or LDTs.

LDTs historically enjoyed "enforcement discretion" from the FDA, meaning the agency chose not to regulate them strictly. CMS oversight, governed by the 1988 Clinical Laboratory Improvement Amendments (CLIA), was far more lenient regarding the device's actual mechanics. CMS focused on the lab’s personnel and paperwork rather than the engineering of the blood-testing box.

Bypassing FDA vs CMS With Clever Definitions

Theranos told the military and retail partners that its regulatory strategy was sound. Lieutenant Colonel David Shoemaker, a regulatory expert for the Army, was one of the few to challenge this. He noted that the FDA would never allow a device to be deployed nationwide without formal clearance.

Holmes and her team countered by saying their Palo Alto lab’s CLIA certificate was sufficient for any remote testing. They leveraged the fact that federal law 42 CFR Part 493 primarily focuses on the lab's mother base. This legal maneuvering allowed them to bypass the FDA's scrutiny for several years.

Avoiding the Fraud Trap in Modern Business Compliance

Compliance isn't just about following the letter of the law; it's about surviving the spirit of the law. Theranos used its legal shield to ignore failed quality-control checks and inaccurate potassium results. When regulators eventually closed the loophole, the company had no data to support its claims.

Hiding the Evidence from CMS

During a 2012 inspection, a CMS representative visited the Theranos lab but never saw the Edison machines. The company kept the proprietary devices in a separate room called "Normandy" and kept the door locked. The inspector only saw conventional, third-party machines, which satisfied the immediate paperwork requirements.

Theranos also used its legal team, led by David Boies, to threaten employees who questioned the arbitrage. Lawyers used nondisclosure agreements to ensure that the gap between the company's public claims and its laboratory reality remained hidden. This kept the $900 million in venture capital flowing while the technology continued to fail.

Launching Without Validation

The 2013 launch in Walgreens stores was the ultimate test of this strategy. Theranos was forced to dilute finger-stick samples to run them on Siemens analyzers because their own devices couldn't handle the volume. This dilution pushed the blood samples outside the FDA-sanctioned analytic measurement range, a major violation of business compliance.

Auditing Your Regulatory Risk Profile

Every business must eventually face the regulators it tries to avoid. If you're building a company in a regulated space, you can't rely on a jurisdictional gap forever. Use these three steps to ensure your strategy doesn't become a legal liability.

1. Map every overlapping agency requirement for your product. Theranos failed because it ignored the FDA’s long-term authority over medical devices. Identify which agency has the ultimate power to shut you down and prioritize their standards early.

2. Establish independent validation for all core claims. Don't hide behind "trade secrets" when a regulator asks for proof of accuracy. If your product relies on a loophole, ensure the underlying data would pass a traditional audit if the loophole closed tomorrow.

3. Create a internal culture of transparent reporting. Employees like Tyler Shultz and Erika Cheung tried to warn the company about failed quality-control tests. A business that suppresses internal red flags will eventually lose its legal protection when those employees go to the authorities.

Limits of Arbitrage Outcomes

Critics of the regulatory arbitrage model argue it encourages companies to prioritize legal engineering over product engineering. At Theranos, the focus on bypassing the FDA led to a complete lack of scientific rigor. Experts like Dr. Phyllis Gardner at Stanford noted that the company’s original patch idea was physically impossible from the start.

Others point out that this strategy only works when the company has enough capital and political influence to keep regulators at bay. Theranos spent millions on Boies Schiller Flexner to fight a patent battle against Richard Fuisz to protect its perceived monopoly. Once the legal shield was pierced by investigative journalism and agency whistleblowers, the entire $9 billion valuation vanished almost overnight.

Regulatory arbitrage provides a high-speed path to market but carries extreme legal risk if the underlying technology fails. Businesses that exploit jurisdictional gaps must ensure their products eventually meet the highest safety standards to survive long-term scrutiny. Audit your current regulatory strategy to identify if you are relying on a loophole that could be closed by future legislation.